PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-57.23%
Revenue decline while RVPH shows 0.00% growth. Joel Greenblatt would examine competitive position erosion.
No Data
No Data available this quarter, please select a different quarter.
-57.23%
Gross profit decline while RVPH shows 0.00% growth. Joel Greenblatt would examine competitive position.
No Data
No Data available this quarter, please select a different quarter.
-15.08%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-0.47%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.89%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-10.89%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
3.20%
D&A growth less than half of RVPH's 37606.76%. David Dodd would verify if efficiency is sustainable.
5.74%
EBITDA growth 1.25-1.5x RVPH's 4.37%. Bruce Berkowitz would examine sustainability.
-120.42%
EBITDA margin decline while RVPH shows 0.00% growth. Joel Greenblatt would examine position.
5.53%
Operating income growth 1.25-1.5x RVPH's 4.38%. Bruce Berkowitz would examine sustainability.
-120.91%
Operating margin decline while RVPH shows 0.00% growth. Joel Greenblatt would examine position.
3.85%
Other expenses growth while RVPH reduces costs. John Neff would investigate differences.
5.62%
Pre-tax income growth while RVPH declines. John Neff would investigate advantages.
-120.69%
Pre-tax margin decline while RVPH shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
5.62%
Net income growth while RVPH declines. John Neff would investigate advantages.
-120.69%
Net margin decline while RVPH shows 0.00% growth. Joel Greenblatt would examine position.
13.79%
EPS growth while RVPH declines. John Neff would investigate advantages.
13.79%
Diluted EPS growth while RVPH declines. John Neff would investigate advantages.
10.10%
Share count reduction exceeding 1.5x RVPH's 39.46%. David Dodd would verify capital allocation.
10.10%
Diluted share reduction exceeding 1.5x RVPH's 39.46%. David Dodd would verify capital allocation.